Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions

International Journal of Hematology

Volumn 76, Issue 1, 2002, Pages 94-97

  Makita, Masanori ^a,b   Maeda, Yoshinobu ^a   Takenaka, Katsuto ^a   Shinagawa, Katsuji ^a   Sunami, Kazutaka ^a   Hiramatsu, Yasushi ^a   Fujii, Nobuharu ^a   Ishimaru, Fumihiko ^a   Ikeda, Kazuma ^a   Niiya, Kenji ^a   Yoshino, Tadashi ^a   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DLI; Early cyclosporine tapering; GVL; NK cell lymphoma

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; LYMPHOMA; NATURAL KILLER CELL; ADULT; ALLOTRANSPLANTATION; CASE REPORT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE TRANSFUSION; PATHOLOGY; T CELL LYMPHOMA;

ADULT; CYCLOSPORINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LEUKOCYTE TRANSFUSION; LYMPHOMA, T-CELL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 17144473414     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982726     Document Type: Article

References (16)

1. Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol Oncol. 1997;15:71-79.
2. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;84:1050-1055.
3. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19:121-127.
4. Harada M, Nagafuji K, Fujisaki T, et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. J Hematother. 1996;5:63-71.
5. Oji Y, Oka Y, Tatekawa T, et al. Successful treatment of relapsed T-cell non-Hodgkin's lymphoma with allogeneic peripheral blood stem cell transplantation with double conditioning. Int J Hematol. 1999;69:263-267.
6. Nawa Y, Takenaka K, Shinagawa K, et al. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:1321-1322.
7. Takami A, Nakao S, Yachie A, et al. Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21:1279-1282.
8. Teshima T, Miyaji R, Fukuda M, Ohshima K. Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. Lancet. 1996;347:1124.
9. Carlens S, Aschan J, Remberger M, Dilber M, Ringden O. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow Transplant. 1999;24:629-635.
10. Abraham R, Szer J, Bardy P, Grigg A. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplant. 1997;20:773-777.
11. Aschan J, Ringden O, Andstrom E, Ljungman P, Lonnqvist B, Remberger M. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transplant. 1994;14:79-87.
12. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation: EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang. 1998;74:321-329.
13. de Lima M, Bonamino M, Vasconcelos Z, et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant. 2001;27:73-78.
14. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
15. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1191.
16. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.